Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis

British Journal of Dermatology

Volumn 176, Issue 2, 2017, Pages 395-402

  Matsushita, T ^a   Mizumaki, K ^a   Kano, M ^a   Yagi, N ^a   Tennichi, M ^a   Takeuchi, A ^a   Okamoto, Y ^a   Hamaguchi, Y ^a   Murakami, A ^b   Hasegawa, M ^c   Kuwana, M ^d   Fujimoto, M ^e   Takehara, K ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Medical & Biological Laboratories Co Ltd   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5 ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CREATINE KINASE; CYCLOPHOSPHAMIDE; FERRITIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; PROTEIN ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; CORTICOSTEROID; DERMATOLOGICAL AGENT; IFIH1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG PULSE THERAPY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; MALE; MIDDLE AGED; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; COMBINATION DRUG THERAPY; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; METABOLISM; RECURRENT DISEASE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AUTOANTIBODIES; CYCLOPHOSPHAMIDE; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-INDUCED HELICASE, IFIH1; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 85010338128     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14882     Document Type: Article

References (32)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971–82.
2. Callen JP. Dermatomyositis. Lancet 2000; 355:53–7.
3. Krathen MS, Fiorentino D, Werth VP. Dermatomyositis. Curr Dir Autoimmun 2008; 10:313–32.
4. Sato S, Hirakata M, Kuwana M et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52:1571–6.
5. Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54:3682–9.
6. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006; 8:196–203.
7. Matsushita T, Hasegawa M, Fujimoto M et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol 2007; 34:1012–18.
8. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48:607–12.
9. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184:134–53.
10. Hamaguchi Y, Kuwana M, Hoshino K et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147:391–8.
11. Hamaguchi Y, Fujimoto M, Matsushita T et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLOS ONE 2013; 8:e60442.
12. Fiorentino D, Chung L, Zwerner J et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25–34.
13. Narang NS, Casciola-Rosen L, Li S et al. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken) 2015; 67:667–72.
14. Komura K, Fujimoto M, Matsushita T et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci 2005; 40:215–17.
15. Kaji K, Fujimoto M, Hasegawa M et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007; 46:25–8.
16. Gunawardena H, Wedderburn LR, Chinoy H et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60:1807–14.
17. Ichimura Y, Matsushita T, Hamaguchi Y et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71:710–13.
18. Sato S, Hoshino K, Satoh T et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193–200.
19. Nakashima R, Imura Y, Kobayashi S et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 2010; 49:433–40.
20. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46:626–36.
21. Sato S, Kuwana M, Fujita T et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013; 23:496–502.
22. Gono T, Kawaguchi Y, Satoh T et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010; 49:1713–19.
23. Chen Z, Cao M, Plana MN et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 2013; 65:1316–24.
24. Moghadam-Kia S, Oddis CV, Sato S et al. Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68:689–94.
25. Mukae H, Ishimoto H, Sakamoto N et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136:1341–7.
26. Gono T, Sato S, Kawaguchi Y et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 2012; 51:1563–70.
27. Muro Y, Sugiura K, Hoshino K et al. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology 2012; 51:800–4.
28. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344–8.
29. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Eng J Med 1975; 292:403–7.
30. Sato S, Murakami A, Kuwajima A et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLOS ONE 2016; 11:e0154285.
31. Yamasaki Y, Yamada H, Yamasaki M et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007; 46:124–30.
32. Yamaguchi K, Yamaguchi A, Uchida M et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 2015; DOI: 10.3109/14397595.2015.1014140.